Q-omics provides the consensus-scored TGIF2-RAB5IF profile across patient tissues and cancer cell-line models. TGIF2-RAB5IF expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TGIF2-RAB5IF is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TGIF2-RAB5IF RNA expression shows 16,253 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where TGIF2-RAB5IF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGIF2-RAB5IF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGIF2-RAB5IF survival associations across molecular data types. TGIF2-RAB5IF RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGIF2-RAB5IF RNA expression–survival associations across cancer types. High TGIF2-RAB5IF expression shows unfavorable associations in ACC, OV and PAAD, but favorable associations in BRCA, KIRP and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TGIF2-RAB5IF RNA expression.
This table summarizes TGIF2-RAB5IF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TGIF2-RAB5IF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGIF2-RAB5IF shows higher tumor expression in COAD, LUSC, HNSC, STAD, BRCA and LUAD. The COAD box plot shows higher TGIF2-RAB5IF RNA expression in tumor versus normal tissue (log2 FC = +0.272, t-test p < 0.001).
This table shows molecular features associated with TGIF2-RAB5IF in patient tissues and cancer cell lines. In patient samples, TGIF2-RAB5IF shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TGIF2-RAB5IF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
